Scientists target Cancer's weak spot: redox imbalance
NCT ID NCT06600568
First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This study looks for new ways to kill T-cell leukemia and lymphoma cells by disrupting their internal balance of reactive oxygen species. Researchers will test drug combinations in lab-grown cells and in samples from 120 patients with resistant disease. The goal is to find treatments that can selectively eliminate cancer cells while sparing healthy ones.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Drug combinations targeting redox homeostasis (e.g., venetoclax with G6PD inhibitors)
- What this could lead to
- If successful, this could point toward new treatment options for patients with resistant T-cell cancers.
- What could go wrong
- This is an early translational study using lab and patient samples, not a treatment trial. Results may not lead to effective therapies for people.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istituto Nazionale Tumori Fondazione G.Pascale
RECRUITINGNaples, 80100, Italy
-
Istituto Oncologico Veneto
RECRUITINGPadova, 35128, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.